Computational Precision Oncology: Integrating Foundation Ai Models With Multi-Omics And Clinical Intelligence

[1]Dr. Nitin Bhatia,[2]Dr. Lavanya Menon,[3]Mrs. Rupal Desai,[4]Dr. Arvind Kumar

Professor,Department of Neurology, Gandhi Medical College, Hyderabad, India.

Nitinbhatia82@gmail.com

Associate Professor,Department of Pharmacology, Gandhi Medical College, Hyderabad, India.

Lavanyamenon57@gmail.com

Assistant Professor,Department of Physiology, Gandhi Medical College, Hyderabad, India.

Rupaldesai42@gmail.com

Professor,Department of Community Medicine, Gandhi Medical College, Hyderabad, India.

Arvindkumar96@gmail.com

ABSTRACT:
Cancer remains one of the leading causes of morbidity and mortality worldwide despite remarkable advances in molecular diagnostics, targeted therapeutics, immunotherapy, and precision medicine. The rapid expansion of biomedical data generated from radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, laboratory investigations, wearable technologies, and electronic health records has created unprecedented opportunities for computational oncology while simultaneously presenting major analytical challenges. Computational precision oncology has emerged as a transformative discipline that combines artificial intelligence (AI), foundation models, multimodal learning, multi-omics integration, systems biology, and clinical intelligence to enable individualized cancer diagnosis, prognostic prediction, therapeutic optimization, and longitudinal disease monitoring. Foundation AI models pretrained through self-supervised learning acquire generalized biomedical representations that can be adapted across diverse oncology applications including radiogenomics, computational pathology, biomarker discovery, immunotherapy prediction, digital twins, drug discovery, and clinical decision support. Advances in transformer architectures, graph neural networks, multimodal large language models, retrieval-augmented generation, agentic AI, and generative artificial intelligence have substantially accelerated the development of intelligent computational oncology ecosystems capable of integrating heterogeneous biomedical information into unified patient-centered representations. Despite remarkable progress, important challenges remain regarding multimodal data harmonization, computational scalability, explainability, interoperability, cybersecurity, regulatory validation, and equitable implementation. This review provides a comprehensive overview of computational precision oncology, emphasizing the integration of foundation AI models, multi-omics, and clinical intelligence for next-generation personalized cancer care.[1]

Keywords: Computational oncology, Foundation models, Precision oncology, Multi-omics, Artificial intelligence, Clinical intelligence, Digital pathology, Medical imaging, Personalized medicine, Clinical decision support.

Received Date: 5 December 2025**; Accepted Date:** 15 December 2025**; Published Date:** 20 December 2025.

1.Introduction

Cancer is a biologically heterogeneous disease characterized by genomic instability, epigenetic alterations, transcriptional dysregulation, metabolic reprogramming, immune heterogeneity, and dynamic interactions between malignant cells and the surrounding tumor microenvironment. Although precision medicine has significantly improved patient outcomes through molecular diagnostics and targeted therapies, patients with apparently similar pathological diagnoses frequently demonstrate markedly different therapeutic responses and long-term clinical outcomes because of the extraordinary complexity of tumor biology.[2]

Modern oncology continuously generates enormous quantities of heterogeneous biomedical information through computed tomography, magnetic resonance imaging, positron emission tomography, mammography, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable biosensors, electronic health records, and longitudinal clinical documentation. While each modality contributes valuable biological insight, conventional computational approaches often analyze these datasets independently, limiting comprehensive patient-level understanding.[3]

Artificial intelligence has emerged as one of the most transformative technologies in computational oncology by enabling automated interpretation of complex biomedical information. More recently, foundation AI models have fundamentally changed computational medicine by learning generalized biomedical representations capable of supporting numerous downstream oncology applications through transfer learning and multimodal reasoning.[4]

The convergence of foundation AI models, multi-omics technologies, and clinical intelligence is therefore redefining computational precision oncology by enabling increasingly integrated, adaptive, and patient-centered cancer care across the entire clinical workflow.[5]

2.Evolution of Computational Precision Oncology

Computational oncology has evolved considerably over recent decades. Early computational systems primarily relied on statistical analyses and rule-based algorithms that supported limited diagnostic and prognostic applications. Although these approaches provided valuable clinical insights, they lacked adaptability and struggled to analyze highly complex biomedical datasets.[6]

Machine learning introduced predictive modeling capable of identifying nonlinear relationships among clinical variables, imaging characteristics, molecular biomarkers, and patient outcomes. Deep learning further revolutionized oncology through automated extraction of hierarchical representations from radiological imaging, digital pathology, genomic sequencing, and physiological data.

Transformer architectures subsequently enabled efficient modeling of heterogeneous biomedical information through self-attention mechanisms, whereas foundation models extended these capabilities through large-scale self-supervised pretraining on multimodal biomedical datasets.

Today, computational precision oncology integrates foundation AI models, multimodal learning, graph neural networks, systems biology, and large language models into intelligent computational ecosystems capable of supporting personalized cancer care throughout diagnosis, treatment, and survivorship.[7]

3.Foundation AI Models in Computational Oncology

Foundation AI models differ fundamentally from conventional machine learning systems because they are pretrained on extremely large biomedical datasets before adaptation to specialized clinical tasks. Rather than learning isolated prediction tasks, foundation models acquire generalized biological, molecular, anatomical, and clinical representations transferable across multiple oncology applications.[8]

Self-supervised learning enables discovery of latent biomedical structure without requiring extensive manual annotation. Contrastive learning aligns heterogeneous biomedical modalities including radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory investigations, and clinical documentation into shared computational embedding spaces.

Transformer architectures provide cross-modal attention mechanisms capable of integrating complementary biomedical information, whereas graph neural networks model interactions among genes, proteins, signaling pathways, immune responses, imaging biomarkers, and therapeutic targets.

DOI: https://doi.org/10.65477/ijmdas.2025.v1.i6.11

These computational principles substantially improve transfer learning, few-shot learning, zero-shot learning, and generalizability across multiple cancer types and healthcare systems.[9]

4.Computational Architecture

Modern computational precision oncology platforms consist of multiple interconnected computational layers responsible for multimodal biomedical data acquisition, preprocessing, representation learning, multimodal fusion, predictive modeling, longitudinal monitoring, and intelligent clinical decision support.[10]

The acquisition layer collects radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable sensor data, medication history, treatment records, and electronic health documentation. Advanced preprocessing pipelines subsequently normalize imaging studies, harmonize molecular datasets, encode clinical narratives using natural language processing, and synchronize longitudinal patient information.

Large transformer-based neural networks convert heterogeneous biomedical information into unified computational embeddings through self-supervised learning. Downstream adaptation modules fine-tune these generalized representations for diagnosis, prognostic prediction, molecular characterization, biomarker discovery, therapeutic optimization, toxicity estimation, and survival analysis.

Continuous incorporation of longitudinal clinical information enables adaptive computational intelligence that evolves alongside changing patient conditions throughout the cancer care continuum.[11]

5.Multi-Omics Integration

Multi-omics technologies—including genomics, transcriptomics, proteomics, metabolomics, epigenomics, immunomics, lipidomics, microbiomics, and single-cell sequencing—provide comprehensive characterization of cancer biology across multiple molecular layers. Integration of these heterogeneous biological datasets remains one of the greatest computational challenges in precision oncology.[12]

Foundation AI models utilize transformer architectures, graph neural networks, multimodal learning, and biological knowledge graphs to identify interactions among genes, proteins, signaling pathways, metabolites, immune responses, and therapeutic targets.

Artificial intelligence integrates these complementary molecular layers into unified computational representations that improve molecular subtype classification, biomarker discovery, drug response prediction, therapeutic resistance analysis, and systems biology research while strengthening personalized precision medicine beyond isolated genomic analysis.[13]

6.Medical Imaging and Digital Pathology

Radiological imaging and digital pathology represent two of the most important biomedical modalities within computational oncology. Medical imaging provides non-invasive assessment of tumor morphology, vascularity, metabolism, anatomical relationships, and longitudinal disease progression, whereas digital pathology provides microscopic characterization of tissue architecture, cellular morphology, immune infiltration, stromal remodeling, angiogenesis, and molecular biomarkers.[14]

Foundation AI models integrate radiomics and computational pathology into unified multimodal representations that support tumor detection, disease classification, prognostic prediction, treatment response assessment, and molecular characterization.

These integrated computational representations substantially improve diagnostic reproducibility while strengthening precision oncology across diverse cancer types and healthcare environments.[15]

7.Clinical Intelligence and Electronic Health Records

DOI: https://doi.org/10.65477/ijmdas.2025.v1.i6.11

Clinical intelligence extends beyond imaging and molecular biology by incorporating electronic health records, laboratory investigations, medication history, physician documentation, wearable biosensors, treatment timelines, and patient-reported outcomes into computational precision oncology.[16]

Natural language processing extracts clinically relevant information from pathology reports, radiology reports, discharge summaries, multidisciplinary tumor board discussions, and clinical guidelines. Foundation AI models subsequently integrate these structured and unstructured datasets into continuously evolving patient-specific computational representations.

These comprehensive clinical intelligence systems improve diagnostic reasoning, therapeutic planning, toxicity monitoring, recurrence prediction, and survivorship care while reducing fragmentation of healthcare information.[17]

8.Multimodal Learning Across the Clinical Workflow

The defining characteristic of computational precision oncology is seamless integration of heterogeneous biomedical information across the entire clinical workflow. Foundation AI models simultaneously analyze imaging, pathology, genomics, laboratory biomarkers, wearable technologies, electronic health records, and longitudinal patient trajectories to generate unified patient-centered computational representations.[18]

Multimodal transformer architectures preserve complementary biological information while graph neural networks model complex relationships among molecular pathways, imaging biomarkers, therapeutic targets, and clinical outcomes. These integrated computational ecosystems enable comprehensive reasoning across diagnosis, prognostic prediction, therapeutic optimization, disease monitoring, and survivorship management.

By continuously learning from multimodal biomedical information, foundation AI models provide increasingly personalized clinical intelligence that supports evidence-based precision oncology throughout the patient's cancer journey.[19]

9.Precision Cancer Diagnosis Through Foundation AI Models

One of the most important clinical applications of computational precision oncology is the development of highly accurate diagnostic systems capable of integrating radiological imaging, digital pathology, multi-omics, laboratory biomarkers, and longitudinal clinical information into comprehensive patient-specific computational representations. Unlike conventional artificial intelligence systems that analyze individual data modalities independently, foundation AI models perform multimodal reasoning across the entire clinical workflow.[20]

Artificial intelligence combines imaging-derived radiomic biomarkers, histopathological characteristics, genomic alterations, transcriptomic signatures, proteomic profiles, laboratory investigations, and electronic health records to improve tumor detection, molecular subtype classification, disease staging, recurrence prediction, and individualized risk assessment.

These generalized computational representations substantially improve diagnostic consistency while reducing observer variability and supporting multidisciplinary oncology teams through evidence-based clinical decision support.

10.Personalized Therapeutics and Adaptive Treatment Planning

Personalized treatment planning represents one of the greatest strengths of computational precision oncology. Foundation AI models integrate imaging, pathology, genomics, laboratory biomarkers, treatment history, physiological monitoring, and patient-specific clinical characteristics into unified computational frameworks capable of supporting individualized therapeutic decision-making.[21]

Machine learning algorithms estimate treatment response, recurrence probability, progression-free survival, overall survival, treatment-related

DOI: https://doi.org/10.65477/ijmdas.2025.v1.i6.11

toxicity, and mechanisms of therapeutic resistance across chemotherapy, targeted therapy, endocrine therapy, immunotherapy, radiation therapy, surgery, and multimodal treatment combinations.

Continuous incorporation of updated clinical information enables adaptive treatment recommendations that evolve throughout disease progression, allowing clinicians to optimize therapy according to changing biological characteristics and patient health status.

11.Immunotherapy and Tumor Microenvironment Intelligence

The tumor microenvironment exerts profound influence on cancer progression and responsiveness to immunotherapy. Computational precision oncology integrates radiological imaging, computational pathology, transcriptomics, immunomics, spatial biology, laboratory biomarkers, and longitudinal clinical outcomes into comprehensive computational representations of tumor–immune interactions.[22].Foundation AI models quantify tumor-infiltrating lymphocytes, immune checkpoint expression, cytokine signaling pathways, stromal architecture, angiogenesis, and immune-cell spatial organization to estimate responsiveness to immune checkpoint inhibitors, CAR-T cell therapies, cancer vaccines, bispecific antibodies, and adoptive cellular therapies.

These multimodal computational models improve prediction of immunotherapeutic outcomes while supporting increasingly personalized treatment strategies tailored to each patient's unique immune landscape.

12.Drug Discovery and Translational Oncology

Foundation AI models are transforming oncology drug discovery by integrating molecular biology, systems pharmacology, structural biology, pharmacogenomics, and clinical outcome data into generalized computational frameworks. Artificial intelligence identifies novel therapeutic targets, predicts drug-target interactions, estimates toxicity profiles, and models mechanisms of therapeutic resistance.[23]

Generative AI further accelerates pharmaceutical innovation by designing candidate molecules, predicting protein structures, simulating molecular interactions, and generating synthetic biomedical datasets that facilitate preclinical research and hypothesis generation.

Computational precision oncology also supports adaptive clinical trial design through molecular eligibility assessment, patient stratification, outcome prediction, and identification of patients most likely to benefit from investigational therapies.

13.Digital Twins and Intelligent Clinical Decision Support

The convergence of foundation AI models with digital twin technology is creating continuously evolving computational representations of individual cancer patients capable of integrating imaging, pathology, multi-omics, wearable biosensors, laboratory investigations, treatment history, and longitudinal clinical information into adaptive virtual patient models.[24]

Artificial intelligence continuously updates these digital twins as new patient information becomes available, enabling simulation of disease progression, therapeutic response, toxicity, recurrence, and survival before clinical intervention.

Within routine oncology practice, intelligent clinical decision-support platforms integrate multidisciplinary biomedical information into interactive dashboards that provide individualized diagnostic summaries, therapeutic recommendations, toxicity estimates, recurrence predictions, and survivorship planning while maintaining physician oversight.

14.Explainability, Trustworthiness, and Clinical Translation

Although foundation AI models demonstrate remarkable predictive capabilities, successful clinical implementation requires transparency, interpretability, and clinician confidence. Explainable artificial intelligence (XAI) enables healthcare professionals to understand computational reasoning through attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, uncertainty estimation, and counterfactual explanations that identify the biological variables contributing most strongly to model predictions.[25]

Several important implementation challenges remain. Computational precision oncology requires standardized multimodal datasets, secure computational infrastructure, interoperability across healthcare systems, prospective multicenter validation, continuous monitoring for algorithmic bias, and robust cybersecurity measures.

Patient privacy, regulatory approval, equitable access, standardized reporting guidelines, and transparent governance frameworks will remain essential for responsible translation of foundation AI models into routine oncology practice.

15.Emerging Innovations and Future Perspectives

Future computational precision oncology will increasingly incorporate multimodal foundation models, agentic artificial intelligence, multimodal large language models, digital twins, federated learning, reinforcement learning, spatial multi-omics, liquid biopsy, quantum computing, cloud-native healthcare infrastructure, and Internet of Medical Things (IoMT) technologies into unified intelligent healthcare ecosystems.[26]

These next-generation systems will continuously integrate biomedical information across diagnosis, molecular characterization, therapeutic planning, disease monitoring, survivorship care, and clinical research while supporting adaptive evidence-based clinical reasoning.

Foundation AI models are expected to evolve from predictive algorithms into comprehensive biomedical reasoning systems capable of autonomous knowledge synthesis, workflow optimization, personalized patient communication, and continuous learning from global oncology practice.

16.Discussion

Computational precision oncology represents one of the most important paradigm shifts in modern cancer medicine by integrating foundation AI models, multi-omics technologies, and clinical intelligence into unified computational ecosystems. Unlike conventional artificial intelligence systems that independently analyze isolated biomedical datasets, these integrated platforms generate comprehensive patient-specific representations that support diagnosis, prognostic prediction, molecular characterization, therapeutic optimization, digital twins, drug discovery, and intelligent clinical decision support.[27]

Their ability to harmonize heterogeneous biomedical information substantially strengthens personalized medicine while reducing fragmentation of clinical decision-making throughout the oncology workflow. Nevertheless, successful implementation requires continued advances in explainable artificial intelligence, computational infrastructure, interoperability, regulatory science, cybersecurity, and international collaboration.

17.Conclusion

Computational precision oncology is redefining personalized cancer care by integrating foundation AI models, multi-omics technologies, radiological imaging, digital pathology, laboratory biomarkers, wearable technologies, electronic health records, and longitudinal clinical intelligence into unified computational frameworks capable of supporting every stage of the oncology workflow.[28]

Advances in transformer architectures, multimodal learning, graph neural networks, multimodal large language models, digital twins, federated learning, agentic AI, and generative artificial intelligence are expected to further strengthen these intelligent systems, enabling increasingly accurate diagnosis, adaptive therapeutics, continuous disease monitoring, automated clinical reasoning, and evidence-based decision-making.[29]

Although important scientific, technical, ethical, and regulatory challenges remain, continued interdisciplinary collaboration among oncologists, radiologists, pathologists, molecular biologists,

DOI: https://doi.org/10.65477/ijmdas.2025.v1.i6.11

biomedical engineers, computer scientists, healthcare organizations, and regulatory agencies will accelerate responsible implementation of computational precision oncology, ultimately improving patient outcomes and advancing the future of personalized cancer medicine worldwide.[30]

18.References

1.Synthia,F. et al. (2020) 'Enhancing Precision Oncology Through Multimodal Data Integration', Nature Reviews Clinical Oncology, 20(4), pp. 267-283.

2.Chaudhary,K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.

3.Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.

4.Dr.Ohmini Krishnamurthy Rajendran (Author), ANALYSIS OF DNA-DAMAGE AND CANCER-RELATED GENE EXPRESSION FOLLOWING SPACE-RADIATION EXPOSURE USING NASA OPEN SCIENCE DATA, Vol. 11 No. 5s (2025), International Journal of Advances in Signal and Image Sciences (IJASIS), https://xlescience.org/index.php/IJASIS/article/view/2054, DOI: https://doi.org/10.29284/jqgs5s28

5.Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.

6.Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.

7.Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial, Nature, 616(7956), pp. 259-265.

8.Wei, L. et al. (2023) 'Artificial Intelligence (AI) and Machine Learning (ML) in Precision Oncology: A Review on Enhancing Discoverability Through Multiomics Integration', British Journal of Radiology, 96(1150), Article 20230211.

9.Boehm, K.M. et al. (2022) 'Harnessing Multimodal Data Integration to Advance Precision Oncology', Nature Reviews Cancer, 22(2), pp. 114–126.

10.Dr.Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4

11.Dr.Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7

12.Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', Cancer Cell, 40(8), pp. 805-823.

13.Dr.Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5

14.Dr.Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5

15.Dr.Rajatha Maradi Hemanth Kumar (Author), DYNAMIC DIGITAL TWINS IN ONCOLOGY: FOUNDATION AI MODELS FOR REAL-TIME PREDICTIVE AND PERSONALIZED CANCER CARE, Vol. 53 No. 4 (2025), Power System Protection and Control, ISSN-1674-

3415,https://pspac.info/index.php/dlbh/article/view/426, DOI:https://doi.org/10.46121/pspc.53.4.38

16.Dr.Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324, DOI: https://doi.org/10.46121/pspc.52.2.14

17.Dr.Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12

18.Dr.Rajatha Maradi Hemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345, DOI: https://doi.org/10.46121/pspc.52.2.18

19.Dr.Rajatha Maradi Hemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388, DOI: https://doi.org/10.46121/pspc.51.4.7

20.Dr.Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325, DOI: https://doi.org/10.46121/pspc.52.4.14

21.Dr.Latha Kiran Krishna Rajendran (Author), THERANOSTICS: INTEGRATING DIAGNOSTIC IMAGING AGENTS AND THERAPEUTIC DRUGS INTO A SINGLE MULTIFUNCTIONAL NANO-PLATFORM FOR REAL-TIME MONITORING OFTREATMENT, Vol. 53 No. 2 (2025): April-June 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/305, DOI:https://doi.org/10.46121/pspc.53.2.31

22.Dr.Ohmini Krishnamurthy Rajendran (Author), DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING, Vol. 53 No. 3 (2025): July-September 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/326, DOI: https://doi.org/10.46121/pspc.53.3.21

23.Dr.Rajatha Maradi Hemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343, DOI: https://doi.org/10.46121/pspc.52.4.16

24.Dr.Ohmini Krishnamurthy Rajendran (Author), DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL Intelligence’DATA, Vol. 53 No. 4 (2025): October-December 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/327, DOI: https://doi.org/10.46121/pspc.53.4.33

25.Joshi,A. et al. (2023) ‘Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis’, npj Precision Oncology, 7(1), p. 28.

26.Huang,S.C. et al. (2020) ‘Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review’, npj Digital Medicine, 3(1), p. 136

27.Dr.Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312, DOI: https://doi.org/10.46121/pspc.52.4.13.

28.Dr.Rajatha Maradi Hemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8

29.Zwanenburg, A. et al. (2023) ‘The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping’, Radiology, 308(2), e221422.

30.Lambin, P. et al. (2017) ‘Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis’, European Journal of Cancer, 48(4), pp. 441-446